President Donald Trump is executing a shock and awe strategy, burying the public in a smoky cloud of flamboyant proposals.

As founder of Coatue Management, Philippe Laffont oversees $26.9 billion invested in more than 80 stocks, and though he buys ...

Trump is executing a shock and awe strategy, burying the public in a smoky cloud of flamboyant proposals that distract from plans that would hit Americans -- like drug prices.

We came across a bullish thesis on Novo Nordisk A/S (NVO) on Long-Term Pick’s Substack by Dan. In this article, we will summarize the bulls’ thesis on NVO.

The FDA’s approval of Ozempic to battle chronic kidney disease “allows us to more broadly address conditions within cardiovascular-kidney-metabolic syndrome, which affects millions of ...

President Donald Trump is executing a shock and awe strategy, burying the public in a smoky cloud of flamboyant proposals.

Donald Trump is executing a shock and awe strategy, burying the public in a smoky cloud of flamboyant proposals. Some, like ending birthright citizenship, ...

The U.S. Centers for Medicare and Medicaid Services has named Novo Nordisk’s Wegovy, Ozempic and Rybelsus as part of the ...

The second round of Medicare Part D price negotiations will feature two drugs familiar to rheumatologists — Ofev and Otezla — ...

The U.S. FDA has approved Novo Nordisk's Ozempic for reducing the risk of kidney failure and disease progression, as well as ...

Ozempic, or semaglutide, can now be used to reduce the risk of worsening kidney disease or kidney failure in adults with type ...

Attorney General Keith Ellison announced a settlement with Novo Nordisk that let's Minnesotans buy its insulin products for ...